Please login to the form below

Not currently logged in
Email:
Password:

GSK's Tykerb misses breast cancer trial endpoint

Phase III trial doesn’t support use of rival to Herceptin for treatment in early-stage HER2-positive breast cancer

GlaxoSmithKline's (GSK) Tykerb was unable to conclusively show an increase disease-free survival (DFS) in a phase III trial intended to support its use in early-stage HER2-positive breast cancer patients.

The results of the TEACH trial were presented last week at the San Antonio Breast Cancer Symposium in the US and revealed that while Tykerb/Tyverb (lapatinib) was able to show a trend towards disease-free survival in  the delayed adjuvant setting following initial surgery or chemotherapy.

After a median follow-up of four years, DFS events occurred in 13 per cent of patients in the lapatinib arm and 17 per cent on placebo. The trial specifically excluded patients who had been treated with Roche's rival drug Herceptin (trastuzumab).

"We are disappointed that the improvement in disease-free survival with lapatinib monotherapy in TEACH did not reach statistical significance," commented Rafael Amado, senior vice president, oncology development, at GSK.

However, "lapatinib combination therapy remains an important treatment option for patients with metastatic HER2-positive breast cancer whose disease has progressed on treatment with trastuzumab-based regimens," he added.

Tykerb was approved for the latter indication in 2007, and generated $360m in sales for GSK in 2010. GSK has however struggled to extend the indications for the product to fulfil its once-touted blockbuster status. In comparison, Herceptin revenues reached $6.8bn last year.

In September, the company decided to drop the monotherapy arm of the ALTTO study in early-stage breast cancer after concluding that Tykerb was unlikely to be as effective as Herceptin when used on its own.

The study is also looking at the two drugs in combination and given sequentially, and will continue to follow-up patients on these regimens, but at best will support use of Tykerb in combination with Herceptin in the adjuvant setting.

Tykerb is also in phase III testing in gastric cancer and squamous cell carcinoma of the head and neck.

12th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...
eyeforpharma Barcelona 2017 highlights: Industry at the brink of transformation
Hear what Anthill's delegates reported back from the biggest eyeforpharma Barcelona yet....

Infographics